Camp4 Therapeutics Corp (CAMP)
Data as of , from SEC Form 4 filings.
See up to 3 months of CAMP. The 7-day demo opens the 1M and 3M ranges and puts CAMP on your watchlist.
Start 7-day demoLatest CAMP insider trades
- Kelly Gold - OfficerOpen-market purchase$40K
Andrew J. Schwab - DirectorOpen-market sale
About Camp4 Therapeutics Corp (CAMP)
Camp4 Therapeutics Corp is an SEC registrant, filing under CIK 0001736730, classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
CAMP Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 6 | 3,225,589 | $4.96M |
| Open-market sale | 6 | 593,613 | $2.50M |
| Grant or award | 1 | 3,179,558 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CAMP insider transactions (Form 4)
5141 Form 4 filings on record, the earliest from Oct 15, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Steven H. Holtzman - Director | Grant or award | Stock Option (Right to Buy) | 9,000 | $0.00 | - | |
| Northpond Ventures II GP, LLC | Other | Common Stock | 1,003,193 | - | - | |
| Northpond Ventures II GP, LLC | Other | Common Stock | 471,415 | - | - | |
| Northpond Ventures II GP, LLC | Open-market purchase | Common Stock | 763,636 | $11.00 | $8.40M | |
| Northpond Ventures II GP, LLC | Other | Series A Prime Preferred Stock | 11,251,624 | - | - | |
| Northpond Ventures II GP, LLC | Other | Series B Preferred Stock | 5,287,303 | - | - | |
| AH Equity Partners Bio I, L.L.C. | Other | Common Stock | 1,398,067 | - | - | |
| AH Equity Partners Bio I, L.L.C. | Open-market purchase | Common Stock | 181,818 | $11.00 | $2.00M | |
| AH Equity Partners Bio I, L.L.C. | Open-market purchase | Common Stock | 545,454 | $11.00 | $6.00M | |
| AH Equity Partners Bio I, L.L.C. | Other | Series A Prime Preferred Stock | 15,001,312 | - | - | |
| AH Equity Partners Bio I, L.L.C. | Other | Series B Preferred Stock | 679,163 | - | - | |
| Enavate Sciences GP, LLC | Other | Common Stock | 2,422,166 | - | - | |
| Enavate Sciences GP, LLC | Open-market purchase | Common Stock | 1,363,636 | $11.00 | $15.00M | |
| Enavate Sciences GP, LLC | Other | Series B Preferred Stock | 27,166,530 | - | - | |
| Polaris Management Co. VII, L.L.C. | Other | Common Stock | 1,250,061 | - | - | |
| Polaris Management Co. VII, L.L.C. | Other | Common Stock | 87,448 | - | - | |
| Polaris Management Co. VII, L.L.C. | Other | Common Stock | 353,718 | - | - | |
| Polaris Management Co. VII, L.L.C. | Other | Common Stock | 24,745 | - | - | |
| Polaris Management Co. VII, L.L.C. | Open-market purchase | Common Stock | 909,090 | $11.00 | $10.00M | |
| Polaris Management Co. VII, L.L.C. | Other | Series A Prime Preferred Stock | 14,020,475 | - | - | |
| Polaris Management Co. VII, L.L.C. | Other | Series A Prime Preferred Stock | 980,829 | - | - | |
| Polaris Management Co. VII, L.L.C. | Other | Series B Preferred Stock | 3,967,234 | - | - | |
| Polaris Management Co. VII, L.L.C. | Other | Series B Preferred Stock | 277,536 | - | - | |
| 5AM Partners VI, LLC | Other | Common Stock | 1,716,055 | - | - | |
| 5AM Partners VI, LLC | Other | Common Stock | 302,770 | - | - | |
| 5AM Partners VI, LLC | Open-market purchase | Common Stock | 909,090 | $11.00 | $10.00M | |
| 5AM Partners VI, LLC | Other | Series A Prime Preferred Stock | 15,002,166 | - | - | |
| 5AM Partners VI, LLC | Other | Series B Preferred Stock | 4,244,770 | - | - | |
| 5AM Partners VI, LLC | Other | Series B Preferred Stock | 3,395,816 | - | - | |
| Amir Nashat - Director | Other | Common Stock | 1,250,061 | - | - | |
| Amir Nashat - Director | Other | Common Stock | 87,448 | - | - | |
| Amir Nashat - Director | Other | Common Stock | 353,718 | - | - | |
| Amir Nashat - Director | Other | Common Stock | 24,745 | - | - | |
| Amir Nashat - Director | Open-market purchase | Common Stock | 909,090 | $11.00 | $10.00M | |
| Amir Nashat - Director | Other | Series A Prime Preferred Stock | 14,020,475 | - | - | |
| Amir Nashat - Director | Other | Series A Prime Preferred Stock | 980,829 | - | - | |
| Amir Nashat - Director | Other | Series B Preferred Stock | 3,967,234 | - | - | |
| Amir Nashat - Director | Other | Series B Preferred Stock | 277,536 | - | - | |
| Andrew J. Schwab - Director | Other | Common Stock | 1,337,592 | - | - | |
| Andrew J. Schwab - Director | Other | Common Stock | 378,463 | - | - | |
| Andrew J. Schwab - Director | Other | Common Stock | 302,770 | - | - | |
| Andrew J. Schwab - Director | Open-market purchase | Common Stock | 909,090 | $11.00 | $10.00M | |
| Andrew J. Schwab - Director | Other | Series A Prime Preferred Stock | 15,002,166 | - | - | |
| Andrew J. Schwab - Director | Other | Series B Preferred Stock | 4,244,770 | - | - | |
| Andrew J. Schwab - Director | Other | Series B Preferred Stock | 3,395,816 | - | - | |
| Josh Mandel-Brehm - Officer | Other | Common Stock | 605 | - | - | |
| Josh Mandel-Brehm - Officer | Other | Series B Preferred Stock | 6,791 | - | - | |
| Richard A. Young - Director | Other | Common Stock | 8,917 | - | - | |
| Richard A. Young - Director | Other | Series A Prime Preferred Stock | 100,014 | - | - | |
| Steven H. Holtzman - Director | Other | Common Stock | 8,917 | - | - | |
| Steven H. Holtzman - Director | Other | Series A Prime Preferred Stock | 100,014 | - | - |
Recent CAMP Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Daniel Tardiff | affiliate | 1,738 | $8K | View on EDGAR |
CAMP insider trading FAQ
What is the latest insider trade for CAMP?
Camp4 Therapeutics Corp (CAMP) had 11 insider filings in the last 90 days, with the most recent on 2026-09-02. The full record for CAMP runs to 41 Form 4 filings, the earliest from 2024-10-15. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CAMP stock?
6 insider purchases of CAMP were filed in the last 90 days, totaling $4.96M.
How many insiders are selling CAMP stock?
6 insider sales of CAMP were filed in the last 90 days, totaling $2.50M.
Where can I see CAMP SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CAMP Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Kelly Gold view on EDGAR
- - Andrew J. Schwab view on EDGAR
- - Andrew J. Schwab view on EDGAR
- - Andrew J. Schwab view on EDGAR
- - Daniel Tardiff view on EDGAR
- - 5AM Partners VI, LLC view on EDGAR
- - Andrew J. Schwab view on EDGAR
- - Richard A. Young view on EDGAR
- - Yuri Maricich view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where CAMP's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CAMP with a 7-day demo
- CAMP on your watchlist
- Every CAMP Form 4 filing on record
- Up to 3 months of CAMP price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
